These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17934364)

  • 21. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients.
    Peñalver FJ; Jiménez-Yuste V; Almagro M; Alvarez-Larrán A; Rodríguez L; Casado M; Gallur L; Giraldo P; Hernández R; Menor D; Rodríguez MJ; Caballero D; González R; Mayans J; Millán I; Cabrera JR;
    Ann Hematol; 2006 Jun; 85(6):400-6. PubMed ID: 16550390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary immune thrombocytopenic purpura.
    Liebman HA; Stasi R
    Curr Opin Hematol; 2007 Sep; 14(5):557-73. PubMed ID: 17934365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP).
    Schwartz J; Leber MD; Gillis S; Giunta A; Eldor A; Bussel JB
    Am J Hematol; 2003 Feb; 72(2):94-8. PubMed ID: 12555211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune thrombocytopenic purpura: the treatment paradigm.
    Stasi R
    Eur J Haematol Suppl; 2009 Mar; (71):13-9. PubMed ID: 19200303
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura.
    El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS
    Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of adult idiopathic thrombocytopenic purpura.
    Cines DB; McMillan R
    Annu Rev Med; 2005; 56():425-42. PubMed ID: 15660520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splenectomy for idiopathic thrombocytopenic purpura: a five-year retrospective review.
    Gibson M; Sehon JK; White S; Zibari GB; Johnson LW
    Am Surg; 2000 Oct; 66(10):952-4; discussion 955. PubMed ID: 11261623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
    Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
    Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract]   [Full Text] [Related]  

  • 32. Sequence of treatments for adults with primary immune thrombocytopenia.
    George JN
    Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoclonal antibodies in the treatment of immune thrombocytopenic purpura (ITP).
    Gómez-Almaguer D
    Hematology; 2012 Apr; 17 Suppl 1():S25-7. PubMed ID: 22507772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
    Aggarwal A; Catlett JP
    South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Updated guidelines for immune thrombocytopenic purpura: Expanded management options.
    DeSouza S; Angelini D
    Cleve Clin J Med; 2021 Dec; 88(12):664-668. PubMed ID: 34857604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Idiopathic thrombocytopenic purpura: beyond consensus.
    Medeiros D; Buchanan GR
    Curr Opin Pediatr; 2000 Feb; 12(1):4-9. PubMed ID: 10676767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases.
    Vianelli N; Galli M; de Vivo A; Intermesoli T; Giannini B; Mazzucconi MG; Barbui T; Tura S; Baccaranion M;
    Haematologica; 2005 Jan; 90(1):72-7. PubMed ID: 15642672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of idiopathic thrombocytopenic purpura: new approach to refractory patients.
    Bussel JB
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):91-8. PubMed ID: 11226007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idiopathic thrombocytopenic purpura in adults.
    Provan D; Newland A
    J Pediatr Hematol Oncol; 2003 Dec; 25 Suppl 1():S34-8. PubMed ID: 14668637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura.
    Arnold DM; Dentali F; Crowther MA; Meyer RM; Cook RJ; Sigouin C; Fraser GA; Lim W; Kelton JG
    Ann Intern Med; 2007 Jan; 146(1):25-33. PubMed ID: 17200219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.